Genedrive PLC (AIM: GDR) has announced that its Genedrive® MT-RNR1 ID Kit has been implemented at Erasmus MC University Medical Center in Rotterdam, expanding the international adoption of its rapid
Genedrive Expects FY26 Income to Rise 40% as NHS Adoption Expands
genedrive plc (AIM: GDR) expects to report total income of £1.4 million for the year ended 30 June 2026, up from around £1.0 million in FY25 and in line with
Genedrive technology showcased in Parliament
Genedrive plc (AIM: GDR) has highlighted comments from UK Health Minister Preet Kaur Gill MP, who cited rapid pharmacogenetic testing for antibiotic-induced hearing loss as a practical example of personalised
genedrive partners with Thermo Fisher on NHS testing
genedrive plc (AIM: GDR) has entered into a product development collaboration with Thermo Fisher Scientific to develop a high-throughput CYP2C19 pharmacogenetic test for deployment on Thermo Fisher’s QuantStudio™ 5 Dx